贝伐珠单抗治疗三阴性乳腺癌相关进展  

Progress on using bevacizumab in treating triple-negative breast cancer

作　　者：潘战宇[1] 李彦昕[2] 姜战胜[1] 谢广茹[1] 

机构地区：[1]天津医科大学肿瘤医院中西医结合科、国家肿瘤临床医学研究中心、乳腺癌防治教育部重点实验室、天津市肿瘤防治重点实验室,天津市300060 [2]内蒙古通辽市医院肿瘤外科

出　　处：《中国肿瘤临床》2015年第14期716-719,共4页Chinese Journal of Clinical Oncology

摘　　要：三阴性乳腺癌是指雌激素受体(estrogen receptor,ER)、孕激素受体(progesterone receptor,PR)及人类表皮生长因子受体-2(human epidermal growth factor receptor-2,HER-2)均为阴性的乳腺癌。三阴性乳腺癌患者因不具备内分泌治疗和抗HER-2治疗的靶点,因此在治疗方面以化疗为主。贝伐珠单抗作为一种针对人血管内皮生长因子(vascular endothelial growth factor,VEGF)的单克隆抗体,在三阴性乳腺癌中是仅有的使用比较广泛的靶向治疗药物。本文将就贝伐珠单抗在三阴性乳腺癌的新辅助治疗、辅助治疗和晚期一线、二线治疗方面的相关研究进行综述。The characteristic of triple-negative breast cancer （TNBC） is defined as ER-negative, PgR-negative, and HER2-nega- tire. Chemotherapy is primarily used to treat TNBC because TNBC patients do not have the targets of endocrine therapy and HER-2 therapy. Bevacizumab is the only widely used target drug in TNBC and acts as a monoclonal antibody target on human vascular endo- thelial growth factor. This article provides a review on the progress of using bevacizumab in neo-adjuvant therapy, adjuvant therapy, and first- and second-line treatment of TNBC.

关 键 词：三阴性乳腺癌 贝伐珠单抗 新辅助 辅助 晚期 治疗 

分 类 号：R737.9[医药卫生—肿瘤]